Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Common Equity (2023 - 2025)

Beta Bionics' Common Equity history spans 3 years, with the latest figure at $287.6 million for Q4 2025.

  • For Q4 2025, Common Equity rose 217.22% year-over-year to $287.6 million; the TTM value through Dec 2025 reached $287.6 million, up 217.22%, while the annual FY2025 figure was $287.6 million, 217.22% up from the prior year.
  • Common Equity for Q4 2025 was $287.6 million at Beta Bionics, down from $294.8 million in the prior quarter.
  • Across five years, Common Equity topped out at $313.8 million in Q1 2025 and bottomed at -$245.4 million in Q4 2024.
  • The 3-year median for Common Equity is -$203.1 million (2023), against an average of $9.4 million.
  • The largest annual shift saw Common Equity decreased 20.8% in 2024 before it surged 246.39% in 2025.
  • A 3-year view of Common Equity shows it stood at -$203.1 million in 2023, then dropped by 20.8% to -$245.4 million in 2024, then soared by 217.22% to $287.6 million in 2025.
  • Per Business Quant, the three most recent readings for BBNX's Common Equity are $287.6 million (Q4 2025), $294.8 million (Q3 2025), and $301.6 million (Q2 2025).